Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 471 days ago
Stocktwits
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tags: REGN
Stocktwits
read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 290 days ago
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 324 days ago
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1052 days ago
Taiwan Stock Market Tipped To Open In The Green

Taiwan Stock Market Tipped To Open In The Green

The Taiwan stock market bounced higher again on Friday, one day after snapping the four-day winning streak in which it had surged almost 1,250 points or 6.2 percent. The Taiwan Stock Exchange now sits just above the 21,840-point plateau although it's likely to tick higher again on Monday.
RTTNews | 7 minutes ago
Higher Open Anticipated For Singapore Stock Market

Higher Open Anticipated For Singapore Stock Market

The Singapore stock market has moved higher in two straight sessions, collecting more than 25 points or 0.6 percent along the way. The Straits Times Index now sits just beneath the 3,900-point plateau and it may add to its winnings on Monday.
RTTNews | 37 minutes ago
Malaysia Stock Market Tipped To Open To The Upside

Malaysia Stock Market Tipped To Open To The Upside

The Malaysia stock market has ticked lower in back-to-back sessions, shedding almost a dozen points or 0.8 percent along the way. The Kuala Lumpur Composite Index now sits just above the 1,570-point plateau although it may find support on Monday.
RTTNews | 1h 7min ago
Japan Stock Market May Find Support On Monday

Japan Stock Market May Find Support On Monday

The Japanese stock market has moved lower in three straight sessions, dropping almost 450 points or 1.3 percent along the way. The Nikkei 225 now sits just above the 37,750-point plateau although it may find traction on Monday.
RTTNews | 1h 22min ago
Tools
Ekonomisko notikumu kalendārs
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Streaming Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Kopiena
Kopiena
Sistēmas
Most Popular Systems
Stratēģijas
Konkursi
Forex Charts
Komunikācijas apskats
Sentiment Indicator
Apskats
Brokeri
Prop Trading Firms
VPS Services
Signālu provaiders
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Padomnieki (Expert Advisors)
Crypto Exchanges
Trading Courses
Brokeri
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Press Release
Platforma
Logrīki
Funkcijas
API
RSS
Stock Portfolio
Affiliate Software
Izvērsta diagramma
Atbalsts
BUJ
Palīdzība
Kontaktēties ar mums
Ziņotas par kļūdu!
Par
Blogs
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.